Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals3.86%-1.00 ppManaged Health Care1.59%-0.66 ppBiotechnology1.84%-0.45 ppLife Sciences Tools & Services1.16%-0.43 ppHealth Care Equipment2.47%-0.37 ppHealth Care Services0.49%-0.16 ppHealth Care Distributors0.37%-0.06 ppHealth Care Technology0.03%+0.03 ppHealth Care Facilities0.18%-0.03 ppHealth Care Supplies0.14%-0.01 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.84%
Industry change · 12M
-0.45 pp
Biotechnology · contribution
-0.449 pp
Company participation
25%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Nov 2024 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Amgen → AMGN | United States | $152.1bn | 0.336% | -0.098 pp | -0.114 pp | +8.1% | No |
| Regeneron Pharmaceuticals → REGN | United States | $70.5bn | 0.156% | -0.113 pp | -0.086 pp | -8.9% | No |
| AbbVie → ABBV | United States | $323.3bn | 0.713% | -0.124 pp | -0.070 pp | +33.2% | No |
| Moderna → MRNA | United States | $16.6bn | 0.037% | -0.035 pp | -0.056 pp | -44.6% | No |
| Biogen → BIIB | United States | $23.4bn | 0.052% | -0.020 pp | -0.054 pp | -31.4% | No |
| Gilead Sciences → GILD | United States | $115.4bn | 0.255% | +0.017 pp | -0.043 pp | +25.9% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $120.6bn | 0.266% | -0.043 pp | -0.019 pp | +31.9% | No |
| Incyte → INCY | United States | $14.4bn | 0.032% | +0.001 pp | -0.006 pp | +37.3% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.